Literature DB >> 16085230

SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer.

Yue Hu1, Suzhan Zhang, Jiekai Yu, Jian Liu, Shu Zheng.   

Abstract

Breast cancer has never had any good serum tumor markers. Therefore, we developed and evaluated a proteomics approach to searching for new biomarkers and building diagnostic models. SELDI-TOF-MS ProteinChip was used to detect the serum protein patterns of 49 breast cancer patients, 51 patients with benign breast diseases, and 33 healthy women. The diagnostic models were developed and validated using bioinformatics tools such as artificial neural networks and discriminant analysis. In total, four models were built and their sensitivities and specificities were satisfactory. The abilities of these models to diagnose stage I breast cancer were not worse than for stages II-IV (P>0.05). Four candidate biomarkers of breast cancer were found. The high sensitivity and specificity achieved by this method show great potential for the early detection of breast cancer and facilitation of discovering new and improved biomarkers.

Entities:  

Mesh:

Year:  2005        PMID: 16085230     DOI: 10.1016/j.breast.2005.01.008

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  18 in total

1.  Detection and identification of potential biomarkers of breast cancer.

Authors:  Yuxia Fan; Jiachen Wang; Yang Yang; Qiuliang Liu; Yingzhong Fan; Jiekai Yu; Shu Zheng; Mengquan Li; Jiaxiang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-17       Impact factor: 4.553

2.  A data-mining approach to biomarker identification from protein profiles using discrete stationary wavelet transform.

Authors:  Hussain Montazery-Kordy; Mohammad Hossein Miran-Baygi; Mohammad Hassan Moradi
Journal:  J Zhejiang Univ Sci B       Date:  2008-11       Impact factor: 3.066

3.  Optimizing High-Resolution Mass Spectrometry for the Identification of Low-Abundance Post-Translational Modifications of Intact Proteins.

Authors:  Lisa E Kilpatrick; Eric L Kilpatrick
Journal:  J Proteome Res       Date:  2017-08-08       Impact factor: 4.466

4.  Proteomic Profiling of Invasive Ductal Carcinoma (IDC) using Magnetic Beads-based Serum Fractionation and MALDI-TOF MS.

Authors:  Juan Yang; Jiang Zhu; Kang He; Ling-Yu Zhao; Li-Ying Liu; Tu-Sheng Song; Chen Huang
Journal:  J Clin Lab Anal       Date:  2014-08-17       Impact factor: 2.352

5.  Search for breast cancer biomarkers in fractionated serum samples by protein profiling with SELDI-TOF MS.

Authors:  Annemieke W J Opstal-van Winden; Jos H Beijnen; Arnoud Loof; Waander L van Heerde; Roel Vermeulen; Petra H M Peeters; Carla H van Gils
Journal:  J Clin Lab Anal       Date:  2012-01       Impact factor: 2.352

6.  Combining proteomics, serum biomarkers and bioinformatics to discriminate between esophageal squamous cell carcinoma and pre-cancerous lesion.

Authors:  Xiao-hui Zhai; Jie-kai Yu; Chen Lin; Li-dong Wang; Shu Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2012-12       Impact factor: 3.066

7.  Serum differential protein identification of Xinjiang Kazakh esophageal cancer patients based on the two-dimensional liquid-phase chromatography and LTQ MS.

Authors:  Cui Li; Guo Xia; Zhang Jianqing; Yang Mei; Bai Ge; Zhang Li
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

Review 8.  Breast tumor metastasis: analysis via proteomic profiling.

Authors:  Steve Goodison; Virginia Urquidi
Journal:  Expert Rev Proteomics       Date:  2008-06       Impact factor: 3.940

9.  Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer.

Authors:  Ai-Na Liu; Ping Sun; Jian-Nan Liu; Cai-Yan Yu; Hua-Jun Qu; Ai-Hong Jiao; Liang-Ming Zhang
Journal:  Tumour Biol       Date:  2014-06-29

10.  Mining novel biomarkers for prognosis of gastric cancer with serum proteomics.

Authors:  Fu-Ming Qiu; Jie-Kai Yu; Yi-Ding Chen; Qi-Feng Jin; Mei-Hua Sui; Jian Huang
Journal:  J Exp Clin Cancer Res       Date:  2009-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.